Edwards Lifesciences Forecast, price target & analysts
Edwards Lifesciences Target price 2025 - Analyst rating & recommendation
Edwards Lifesciences Classifications & Recommendation:
Edwards Lifesciences Price Target
| Target Price | $79.51 |
| Price | $71.87 |
| Potential |
10.64%
register free of charge
|
| Number of Estimates | 27 |
|
27 Analysts have issued a price target Edwards Lifesciences 2026 .
The average Edwards Lifesciences target price is $79.51.
This is
10.64%
register free of charge
$90.00
25.23%
register free of charge
$61.00
15.12%
register free of charge
|
|
| A rating was issued by 32 analysts: 14 Analysts recommend Edwards Lifesciences to buy, 17 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Edwards Lifesciences stock has an average upside potential 2026 of
10.64%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 5.44 | 5.81 |
| 8.57% | 6.87% | |
| EBITDA Margin | 29.41% | 29.86% |
| 6.30% | 1.55% | |
| Net Margin | 15.80% | 24.32% |
| 41.53% | 53.94% |
29 Analysts have issued a sales forecast Edwards Lifesciences 2025 . The average Edwards Lifesciences sales estimate is
This results in the following potential growth metrics:
21 Analysts have issued an Edwards Lifesciences EBITDA forecast 2025. The average Edwards Lifesciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Edwards Lifesciences Analysts have issued a net profit forecast 2025. The average Edwards Lifesciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.46 | 2.40 |
| 36.52% | 64.38% | |
| P/E | 29.93 | |
| EV/Sales | 6.69 |
14 Analysts have issued a Edwards Lifesciences forecast for earnings per share. The average Edwards Lifesciences EPS is
This results in the following potential growth metrics and future valuations:
Edwards Lifesciences...
Current Edwards Lifesciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Feb 12 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Feb 12 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 12 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Feb 12 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 13 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Feb 13 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Feb 12 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Feb 12 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 12 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 12 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Jan 30 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
